ESR1 and breast cancer: Importantly, ERX-11 had activity against ER-driven breast cancer cell lines that were either resistant to tamoxifen (MCF-7-TamR,Figure 6A, or MCF-7-HER2,Figure 6B) or to letrozole (MCF-7-LTLT,Figure 6C).